Adaptive Biotechnologies Corp
$ 17.60
-6.03%
12 Jun - close price
- Market Cap 2,816,781,000 USD
- Current Price $ 17.60
- High / Low $ 19.52 / 17.10
- Stock P/E N/A
- Book Value 1.36
- EPS -0.32
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.24 %
- 52 Week High 20.76
- 52 Week Low 9.96
About
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Analyst Target Price
$20.14
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-05 | 2025-11-05 | 2025-08-05 | 2025-05-01 | 2025-02-11 | 2024-11-07 | 2024-08-01 | 2024-05-07 | 2024-02-14 | 2023-11-09 | 2023-08-02 |
| Reported EPS | -0.13 | -0.09 | 0.06 | -0.17 | -0.2 | -0.23 | -0.22 | -0.29 | -0.32 | -0.3 | -0.35 | -0.33 |
| Estimated EPS | -0.16 | -0.18 | -0.14 | -0.24 | -0.31 | -0.24 | -0.27 | -0.33 | -0.34 | -0.33 | -0.34 | -0.35 |
| Surprise | 0.03 | 0.09 | 0.2 | 0.07 | 0.11 | 0.01 | 0.05 | 0.04 | 0.02 | 0.03 | -0.01 | 0.02 |
| Surprise Percentage | 18.75% | 50% | 142.8571% | 29.1667% | 35.4839% | 4.1667% | 18.5185% | 12.1212% | 5.8824% | 9.0909% | -2.9412% | 5.7143% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADPT
2026-06-12 19:39:13
Adaptive Biotechnologies is gaining attention within the healthcare and biotechnology sectors due to its advancements in immune system sequencing technologies. The company's work supports precision medicine, disease monitoring, and diagnostic development. Its focus on immune-driven diagnostics is lifting its momentum and placing it in the Nasdaq Healthcare Focus watchlist.
2026-06-12 10:10:35
Adaptive Biotechnologies (ADPT) saw its shares rally 9.7% recently, closing at $18.73, following robust first-quarter 2026 financial results driven by the growth of its clonoSEQ product and pipeline potential. The Zacks Rank #3 (Hold) stock anticipates a quarterly loss of $0.13 per share and revenues of $67.24 million in its upcoming report. Positive trends in earnings estimate revisions, up 3.6% over the last 30 days, suggest potential for continued price appreciation.
2026-06-11 20:10:23
Adaptive Biotechnologies (ADPT) filed a Form 144 notice indicating a proposed sale of 5,000 common stock shares through Morgan Stanley Smith Barney LLC, valued at $85,350, with an associated date of June 11, 2026. The filing also disclosed recent 10b5-1 sales by Susan Bobulsky, involving 11,000 shares sold on June 4, 2026, for $198,000. Additionally, the excerpt provided context, noting 160,044,392 shares outstanding as of June 11, 2026.
2026-06-10 00:10:23
Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 11,000 shares of the company's common stock for a total of $198,000 on June 4, 2026, pursuant to a pre-arranged trading plan. This sale occurred despite the stock's 59.8% return over the past year, as InvestingPro analysis suggests the stock is currently overvalued. The company recently reported strong Q1 2026 revenues of $70.9 million, surpassing forecasts.
2026-06-09 20:10:15
Adaptive Biotechnologies Corporation held its annual shareholder meeting on June 5, 2026, where shareholders approved the election of two Class I directors, Robert Hershberg and Katey Owen, as well as an advisory vote on 2025 executive compensation. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year with overwhelming support. The meeting outcomes indicate strong shareholder support for the company's governance and compensation practices.
2026-06-09 12:09:10
Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 39,741 shares of company stock for $695,070 on June 4, 2026. This transaction was executed under a Rule 10b5-1 trading plan, even as he simultaneously acquired 19,521 shares through stock option exercises. The company recently reported strong Q1 2026 revenues of $70.9 million, exceeding expectations.
